黑料吃瓜群网

A team of researchers at may have found a way to improve treatment of triple-negative breast cancer.

The researchers found that triple-negative breast tumours with the highest energy usage respond best to chemotherapy because the 鈥榬ecycling stations鈥� that deal with metabolic by-products, called proteasomes, also make cancer more 鈥榲isible鈥� to the immune system.

Conducted in collaboration with the and published in the journal , the discovery could improve treatment responses to the aggressive cancer.

鈥淧revious research has indicated that inhibiting proteasomes could be effective in triple-negative breast cancer, but we have found the opposite to be true,鈥� lead researcher Dr Jodi Saunus said.

鈥淚f we can figure out how to boost the activity of tumour proteasomes, we could improve the effectiveness of chemotherapy and potentially increase the prospects for immunotherapy.鈥�

Dr Saunus鈥檚 research team analysed the molecular features of 3500 breast tumours over two years to make this finding.

Until recently, chemotherapy has been the predominant treatment for triple-negative breast cancer, but research now suggests that immunotherapy 鈥� which activates the body鈥檚 in-built cancer defences 鈥� may also work.

Triple-negative breast cancer is one of the most severe breast cancers because it tends to grow and spread quickly, with many patients experiencing relapse in the lungs, liver or brain.

Because the cancer is negative for the three receptors commonly found in breast cancer cells 鈥� oestrogen, progesterone and HER2 receptors 鈥� hormone therapies are ineffective and treatment usually involves surgery, radiotherapy and cytotoxic chemotherapy, which produce unfavourable side effects.

With funding from the the team is now working on the next phase of the research, which they hope will lead to the development of experimental 鈥榗ancer vaccines鈥� that can help the immune system fight the cancer if it spreads to the brain.

Image credit: 漏stock.adobe.com/au/Africa Studio